Duality Advisers LP Makes New $333,000 Investment in DaVita Inc. (NYSE:DVA)

Duality Advisers LP bought a new position in shares of DaVita Inc. (NYSE:DVA) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 3,182 shares of the company’s stock, valued at approximately $333,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DVA. Hanseatic Management Services Inc. acquired a new stake in DaVita during the 3rd quarter worth $36,000. FinTrust Capital Advisors LLC boosted its position in shares of DaVita by 242.3% during the 3rd quarter. FinTrust Capital Advisors LLC now owns 712 shares of the company’s stock valued at $67,000 after acquiring an additional 504 shares during the last quarter. Tacita Capital Inc acquired a new position in shares of DaVita during the 3rd quarter valued at about $118,000. Federated Hermes Inc. boosted its position in shares of DaVita by 1,284.4% during the 3rd quarter. Federated Hermes Inc. now owns 1,246 shares of the company’s stock valued at $118,000 after acquiring an additional 1,156 shares during the last quarter. Finally, CENTRAL TRUST Co boosted its position in shares of DaVita by 93.3% during the 3rd quarter. CENTRAL TRUST Co now owns 1,448 shares of the company’s stock valued at $137,000 after acquiring an additional 699 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insiders Place Their Bets

In other DaVita news, insider James O. Hearty sold 26,164 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the sale, the insider now directly owns 20,264 shares in the company, valued at $2,424,384.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider James O. Hearty sold 26,164 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the completion of the transaction, the insider now directly owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Javier Rodriguez sold 67,603 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the transaction, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The disclosure for this sale can be found here. Insiders have sold 134,540 shares of company stock worth $16,551,071 over the last three months. Company insiders own 1.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on DVA. StockNews.com raised shares of DaVita from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Barclays began coverage on shares of DaVita in a research report on Wednesday, March 6th. They set an “equal weight” rating and a $133.00 price target on the stock. UBS Group boosted their price target on shares of DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Truist Financial boosted their price objective on shares of DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a report on Tuesday, February 20th. Finally, TheStreet upgraded shares of DaVita from a “c+” rating to a “b-” rating in a report on Wednesday, February 7th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $118.50.

DaVita Stock Up 0.5 %

Shares of DVA opened at $133.50 on Friday. The firm has a market cap of $11.71 billion, a P/E ratio of 18.04, a price-to-earnings-growth ratio of 1.18 and a beta of 1.04. DaVita Inc. has a 12-month low of $71.51 and a 12-month high of $141.54. The company’s 50-day moving average price is $132.12 and its 200 day moving average price is $110.47. The company has a current ratio of 1.19, a quick ratio of 1.13 and a debt-to-equity ratio of 6.65.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, February 13th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.53 by $0.34. The company had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.01 billion. DaVita had a net margin of 5.70% and a return on equity of 64.42%. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.11 earnings per share. On average, sell-side analysts forecast that DaVita Inc. will post 9.23 earnings per share for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.